BioXcel Therapeutics (BTAI) H.C. Wainwright & Co. “HCW@Home” Series 2025 summary

Clinical trial updates and design

• SERENITY At-Home Phase III trial for acute agitation in schizophrenia and bipolar patients is nearing top-line data readout, focusing primarily on safety over a 12-week period with 200 patients randomized to drug or placebo.

• Safety is the primary endpoint, with efficacy as an exploratory endpoint using patient-reported outcomes due to the at-home setting; prior institutional studies showed favorable safety and tolerability.

• The trial has passed two Data Safety Monitoring Board reviews, and adverse events are expected to mirror those seen in institutional settings, mainly somnolence.

• Enrollment was distributed across 22 sites, with balanced representation of schizophrenia and bipolar patients.

• Exploratory efficacy endpoints use a modified Clinical Global Impression scale, with trends in benefit over repeated dosing being assessed.

Regulatory and commercialization strategy

• sNDA preparation is underway, with non-clinical sections completed and clinical data to be added after readout; FDA meeting scheduled for August 20th to confirm sufficiency of clinical program.

• Submission of the sNDA is expected to follow quickly after data readout, with a preparation timeline of four to six months.

• Commercialization in the at-home setting may involve a different pricing and packaging model, with potential for higher pricing flexibility compared to institutional sales.

• Strategic options for commercialization include building a sales force or partnering with a larger company to maximize reach and capital efficiency.

Market opportunity and competitive landscape

• At-home market for acute agitation is estimated to be significantly larger than institutional, with up to 23 million episodes annually, and possibly three to four times greater based on recent research.

• Including dementia-related agitation, the total annual episode market could reach 140–150 million.

• No approved drugs exist for at-home treatment of acute agitation in schizophrenia or bipolar; REXULTI is not a direct competitor as it is approved for chronic agitation in Alzheimer’s, not acute episodes.

• BXCL501 is positioned to address breakthrough episodes not covered by chronic treatments.